Podcast: Play in new window | Download (Duration: 13:46 — 31.5MB)
Subscribe: Apple Podcasts | Spotify | RSS
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Year-In-Review Report: Global Trends in Biopharma Transactions Report. Geoff dives into the insights from the comprehensive report and offers a forward-looking perspective on what 2025 may bring for the biotech industry. Key topics include:
Capital Markets Performance: The XBI ended flat, down 0.2%, underperforming the S&P 500’s 24% gain. However, 2024 saw a 156% increase in capital raised compared to 2022, with IPO and follow-on financings improving in Q4.
Venture Financing Trends: Q4 venture financing remained stable at ~$4B across 43 deals, with Series A and B rounds leading. Mega-rounds grew, including Kailera’s $400M Series A and Metsera’s $215M Series B.
Strategic Transactions: Licensing deal value surged 135% in Q4, driven by early-stage deals, while M&A activity slowed, with no deals exceeding $5B.
Regional Highlights: Europe and Asia saw a rise in venture and licensing activity, with Asia’s cross-border deals and NewCo formations becoming key trends. This will be discussed further in a separate podcast.
Market Outlook for 2025: With a new FTC chair, M&A and licensing deals are expected to rise in 2025. IPO markets will improve with gradually reduced interest rates, though risk aversion remains with private mega-rounds persisting to reduce financing risk.
Geoff offers advice for navigating the current market and highlights Asia’s growing role in global biotech. Stay tuned for our upcoming podcast on Asian markets.
Listen now to gain insights into the evolving biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you.
Subscribe or follow Biotalk on Apple Podcasts | Spotify.